TRPC3 and bronchopulmonary dysplasia: For example, the lung morphological changes in the BPD + group after return to normoxia have not yet been detected, so it remains unknown whether the TRPC3 agonist can improve or delay the development of lung pathological changes in neonatal rats with BPD.